At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Apraglutidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-label, Metabolic Balance Study to Evaluate the Effects of Apraglutide on Intestinal Absorption in Adult Subjects With Short Bowel Syndrome, Intestinal Failure (SBS-IF), and Colon-in-Continuity (CIC)
In Brief
A Phase 2 clinical trial evaluating Apraglutide for Short Bowel Syndrome. Completed, enrolled 10 participants across 2 sites in 2 countries.
Detailed Summary
The primary objective of the trial is to evaluate the safety of apraglutide in adult subjects with SBS-IF and CIC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsShort Bowel Syndrome
CountriesBelgium, France
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartJun 2021
First PostedJul 2021
Primary CompletionJun 2023
TodayJul 2026
First PostedJul 16, 2021
Enrollment StartJun 14, 2021
Primary CompletionJun 6, 2023
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 5.0 years ago
Interventions
Apraglutidedrug
Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.